Recursion Reports First Quarter Financial Results and Provides Business Update

Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid ...

Recursion outlines runway into early 2028 while maintaining 2026 cash operating expenses under $390M

Financial framing remained anchored on the same runway and 2026 cash operating expense guidance, while Q1 2026 highlighted a "30% year-over-year reduction" in cash operating expenses and quarter-end ...
Seeking Alpha

Recursion Pharmaceuticals, Inc. (RXRX) Q4 2023 Earnings Call Transcript

Hi, everybody. I’m Chris Gibson, Co-Founder and CEO of Recursion, and I am really excited to welcome you to our first ever Learnings Call here at Recursion. So what is a learnings call and why are we ...
Hosted on MSN

Master recursion without losing your mind

Recursion can feel like magic until you understand its simple rules: a base case to stop, and a recursive call to repeat. By breaking problems into smaller versions of themselves, recursion makes ...
The Motley Fool

Can Recursion Pharmaceuticals Stock Double in 5 Years? Here's What It Would Take.

Success for just one of Recursion's phase 2 programs could enable the stock to double within five years. However, the odds of success for phase 2 candidates aren't good. Risk-averse investors should ...